Article Information
History
- June 4, 2018.
Article Versions
- You are currently viewing Version 1 of this article (June 4, 2018 - 14:26).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Michael A Kalwat*,1,
- In Hyun Hwang2,
- Jocelyn Macho3,
- Magdalena G Grzemska1,
- Jonathan Z Yang1,
- Kathleen McGlynn1,
- John B MacMillan3 and
- Melanie H Cobb*,1
- 1Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX.
- 2Department of Pharmacy, Woosuk University, South Korea.
- 3Department of Chemistry & Biochemistry, UC Santa Cruz, Santa Cruz, CA
- ↵*Correspondence: Dr. Michael A Kalwat, Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75235, USA; Michael.Kalwat{at}utsouthwestern.edu, Dr. Melanie H Cobb, Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75235, USA; Melanie.Cobb{at}utsouthwestern.edu
Posted June 04, 2018.
Chromomycin A2 potently inhibits glucose-stimulated insulin secretion from pancreatic beta cells
